Observational studyClinical cancer research : an official journal of the American Association for Cancer Research2017
Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.
Open access · bronzeAbstract readObservational Study
In one paragraph
Observational study in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed, 3 pooled it
14.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
103 citing papers in PubMed, 3 syntheses or guidelines pooled it, 160 citations in OpenAlex.
- Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations.Prostate cancer and prostatic diseases · 2020Pooled it
- The Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer Treated With Novel Hormonal Therapy or Chemotherapy: A Systematic Review and Meta-analysis.Frontiers in oncology · 2020Pooled it
- Circulating tumor cells prior to initial treatment is an important prognostic factor of survival in non-small cell lung cancer: a meta-analysis and system review.BMC pulmonary medicine · 2019Pooled it
- AR splice variants in circulating tumor cells of patients with castration-resistant prostate cancer: relation with outcome to cabazitaxel.Molecular oncology · 2019Trial
- Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Trial
- Expression of AR-V7 and ARvClinical cancer research : an official journal of the American Association for Cancer Research · 2019Trial
- Liquid biopsy in the clinical management of tumor of urinary system: current status and future developments.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- Splicing factor TRA2B enhances synthesis of androgen receptor variant AR-V7 in prostate cancer cells.The Journal of clinical investigation · 2026Article
- Phase I multi-center clinical and biomarker study of the dual-action androgen receptor inhibitor ONCT-534.Investigational new drugs · 2026Article
- Alterations in AR-FOXA1 signaling in prostate cancer progression and therapeutic resistance.Journal of the National Cancer Center · 2026Review
- Roles of KHDRBS2 and KHDRBS3 in prostate cancer progression and AR-V7 regulation.Discover oncology · 2025Article
- Androgen receptor splice variant expression and prostate cancer recurrence after salvage therapy.NPJ precision oncology · 2025Article
- Clinical impact of real-time androgen receptor alteration monitoring on metastatic castration-resistant prostate cancer treatment in real-world settings.International journal of cancer · 2025Article
- Molecular analysis of androgen receptor splice variant AR-V3 reveals eminent ambiguity regarding activity and clinical utility.Cancer cell international · 2025Article
- Plasma Preparation Strategies for Extracellular Vesicle-Based Biomarkers in Metastatic Castration-Resistant Prostate Cancer.Journal of extracellular biology · 2025Article
- Phenotypic Plasticity and Androgen Receptor Bypass Drive Cross-Resistance to Apalutamide in Castration-Resistant Prostate Cancer Cell Models.International journal of molecular sciences · 2025Article
- Apolipoprotein E promotes primary resistance to AR-targeted therapy via inducing TRIM25-mediated AR ubiquitination and sensitizes immunotherapy in prostate cancer.Theranostics · 2025Article
- Defining Splicing Factor Requirements for Androgen Receptor Variant Synthesis in Advanced Prostate Cancer.Molecular cancer research : MCR · 2024Article
- Advanced single-cell and spatial analysis with high-multiplex characterization of circulating tumor cells and tumor tissue in prostate cancer: Unveiling resistance mechanisms with the CoDuCo in situ assay.Biomarker research · 2024Article
- Clinical Implementation of a Noninvasive, Multi-Analyte Droplet Digital PCR Test to Screen for Androgen Receptor Alterations.The Journal of molecular diagnostics : JMD · 2024Article
43 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 1 institution in 1 country.
Manish KohliDivision of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota. dehm@umn.edu kohli.manish@mayo.edu.
Yeung HoMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
David W HillmanDivision of Biomedical Statistics and Informatics, Department of Health Sciences, Rochester, Minnesota.
Jamie L Van EttenMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
Christine HenzlerMinnesota Supercomputing Institute, University of Minnesota, Minneapolis, Minnesota.
Rendong YangMinnesota Supercomputing Institute, University of Minnesota, Minneapolis, Minnesota.
Jamie M SpergerDepartment of Medicine, Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin.
Yingming LiMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
Elizabeth TsengPacific Biosciences, Menlo Park, California.
Ting HonPacific Biosciences, Menlo Park, California.
Tyson ClarkPacific Biosciences, Menlo Park, California.
Winston TanDepartment of Medicine, Mayo Clinic, Jacksonville, Florida.
Rachel E CarlsonDivision of Biomedical Statistics and Informatics, Department of Health Sciences, Rochester, Minnesota.
Liguo WangDivision of Biomedical Statistics and Informatics, Department of Health Sciences, Rochester, Minnesota.
Hugues SicotteDivision of Biomedical Statistics and Informatics, Department of Health Sciences, Rochester, Minnesota.
Ho ThaiDepartment of Medicine, Mayo Clinic, Scottsdale, Arizona.
Rafael JimenezDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Haojie HuangDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota.
Peter T VedellDivision of Biomedical Statistics and Informatics, Department of Health Sciences, Rochester, Minnesota.
Bruce W EckloffMedical Genome Facility, Mayo Clinic, Rochester, Minnesota.
Jorge F QuevedoDivision of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota.
Henry C PitotDivision of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota.
Brian A CostelloDivision of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota.
Jin JenDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Eric D WiebenMedical Genome Facility, Mayo Clinic, Rochester, Minnesota.
Kevin A T SilversteinMinnesota Supercomputing Institute, University of Minnesota, Minneapolis, Minnesota.
Joshua M LangDepartment of Medicine, Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin.
Liewei WangDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota.
Scott M DehmMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota. dehm@umn.edu kohli.manish@mayo.edu.
University of Minnesota · US
Funding
TRAINING GRANT IN MICROBIOLOGY/CANCER RESEARCHT32CA009138 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Scott M. Dehm · 1985 to 2026
$11.3MAR Gene Rearrangements and AR Signaling in Prostate CancerR01CA174777 · NCI · UNIVERSITY OF MINNESOTA · PI Scott M. Dehm · 2013 to 2026
$4.9MRole of proinflammatory cytokine-induced AR degradation in castration-resistant prostate cancerR01CA130908 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI HUANG, HAOJIE · 2010 to 2021
$3.5MRole of FOXO1 Inactivation in Prostate TumorigenesisR01CA134514 · NCI · UNIVERSITY OF MINNESOTA · PI HUANG, HAOJIE · 2009 to 2019
$3.3MRole of RUNX2 in prostate cancer intratumoral androgen synthesis and progressionR01CA193239 · NCI · MAYO CLINIC ROCHESTER · PI HUANG, HAOJIE · 2015 to 2019
$1.8MVERSA: An Integrated, Multi-Endpoint Platform for Circulating Tumor Cell AnalysisR01CA181648 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI BERRY, SCOTT M, LANG, JOSHUA MICHAEL · 2014 to 2018
$1.6MNCI NIH HHS R01 CA130908NCI NIH HHS R01 CA134514NCI NIH HHS R01 CA174777NCI NIH HHS R01 CA181648NCI NIH HHS R01 CA193239NCI NIH HHS T32 CA009138
Abstract
PubMed holds no abstract for this paper.
Indexed as
AndrostenesGene Expression Regulation, NeoplasticGenetic VariationProstatic Neoplasms, Castration-ResistantReceptors, AndrogenCell Line, TumorCell ProliferationDisease-Free SurvivalDrug Resistance, NeoplasmHumansMaleNeoplasm MetastasisProspective StudiesProtein IsoformsRNA InterferenceabirateroneAndrostenesProtein IsoformsReceptors, Androgen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.